CD4 and prostate carcinoma: ESR1 binding in regions associated with MS were highly enriched for Th1 CD4+ DNase I hypersensitivity peaks (7.41-fold, p < 0.0002) and those in regions associated with prostate cancer for LNCaP DNase I hypersensitivity peaks (9.39-fold, p < 0.0002).